20250831-开源证券-贝泰妮-300957.SZ-公司信息更新报告_2025H1业绩承压_期待业务调整后利润释放_4页_894kb

Summary

Company Overview

贝泰妮（300957.SZ）是一家专注于敏感肌肤护肤的品牌公司，主营美容护理和化妆品。公司品牌矩阵包括薇诺娜、薇诺娜宝贝、瑷科缦、姬芮、泊美等，并持续完善产品线和渠道布局，线上+线下+OMO渠道相互渗透，OMO渠道新增用户约43.27万户。

• Core Business: Focuses on sensitive skin care, with a "敏感肌PLUS" full-scene solution covering repair, sunscreen, brightening, anti-aging, and post-operative care.
• Product Development: Recently launched new products like the anti-aging "银核 CP" series and physical sunscreen "小金刚"; ongoing innovation in plant-based ingredients from Yunnan.

2025H1 Performance

2025年上半年公司营收同比下降15.4%至23.72亿元，净利润下降49.0%至2.47亿元，部分原因是全品类销售承压及销售费用率上升。

• Financial Breakdown:

  • Revenue: 23.72 billion yuan (YoY -15.4%).
  • Net Profit: 2.47 billion yuan (YoY -49.0%).
  • Gross Margin: 76.0% (up 3.4pct), influenced by higher marketing and operational costs.
  • Key Drivers: All product categories faced pressure; online channel revenue slightly up (+5.9%), while offline (-41.7%) and OMO (-10.0%) channels declined.

• Brand Performance:

  • 薇诺娜: Revenue -18.4% YoY.
  • 薇诺娜宝贝: Revenue +8.6% YoY.
  • 瑳科缦: Revenue +93.9% YoY.
  • 姬芮: Revenue -11.5% YoY.
  • 泊美: Not detailed in reports.

• Channel Analysis:

  • Online: Revenue from Alibaba ecosystem and Douyin platforms increased marginally (+7.4% YoY), but overall online fell -5.9% YoY.
  • Offline: Significant decline (-41.7% YoY), affected by reduced in-store presence.
  • Categories: Skincare revenues led, but medical devices saw sharp drop (-55.8% YoY).

Cost Factors: Sales expenses increased by 8.6pct YoY due to marketing personnel, channel expansion, and ad campaigns.

Financial Projections

The company's forecast remains unchanged: for 2025-2027, expected net profits of 6.72 billion yuan (2025), 8.03 billion (2026), and 9.27 billion yuan (2027), with increasing EPS from 1.59 to 2.19 yuan per share. Current PE ratio is around 29.8-39.8x, still supporting a "Buy" rating.

Business Analysis

• Strengths: Strong brand positioning in sensitive skin care, led by薇诺娜; robust R&D with 16 new plant-based ingredients approved, enhancing product innovation.
• Weaknesses: Current profit pressure from operational adjustments post-market shifts.
• Recommendations: Analyst maintains "Buy" view, anticipating profit rebound after structural improvements. Investment should consider channel optimization and product updates to drive income growth.

Investment Recommendation

• Beitianing retains an "BUY" investment rating due to expected recovery in profitability and market adjustments. Long-term growth potential is affirmed at 9.4-13.4% YoY, reflecting expanding brand reach and refined product offerings. However, risks include channel execution delays or increased competition.

Key Risks

• Channel performance failure to meet expectations.
• Market competition intensification.
• New product launches falling short of demand.